AlphaBio SA develops commercially a novel anti-mycotic, for topical usage for skin infections due to fungi (dermatophytosis). This drug is already used as an anti-bacteria an is known to be safe. From its mode of action, it likely that AlphaBio’s product will be effective even against fungi that are resistant to most current anti-fungal agents. Resistance to anti-fungal agents has indeed become a major public health issue.
